12.1 Collaborative Practice Agreements & Telehealth Practice

Collaborative Practice Agreements & Telehealth Practice

Executive Summary: Advanced ambulatory care pharmacy practice relies heavily on formalized collaborative structures and modern digital health delivery channels. Collaborative Drug Therapy Management (CDTM)—operationalized through Collaborative Practice Agreements (CPAs)—empowers Board Certified Ambulatory Care Pharmacists (BCACPs) to manage complex chronic disease regimens at the top of their professional license. In parallel, statewide protocols expand public health access to preventative pharmacotherapy, while telehealth modalities (synchronous, asynchronous, and remote patient monitoring) remove geographic barriers to specialized Comprehensive Medication Management (CMM).

1. Collaborative Drug Therapy Management (CDTM) & Scope of Practice

Collaborative Drug Therapy Management (CDTM) is a collaborative practice model where a licensed pharmacist enters into a voluntary, formal agreement with one or more physicians (or other authorized prescribers) to deliver advanced clinical pharmacy services. Under CDTM, the prescriber delegates authority to the clinical pharmacist to perform clinical pharmacotherapy functions that traditionally fall under the prescriber's legal scope.

Clinical Scope Delegated Under CDTM

Within the parameters established by state pharmacy practice acts and institutional bylaws, CPAs delegate specific clinical authorities:

• Initiating Drug Therapy: Selecting and starting new guideline-directed medical therapies (GDMT) based on confirmed diagnoses (e.g., initiating an SGLT2 inhibitor or GLP-1 receptor agonist in a patient with type 2 diabetes and chronic kidney disease).
• Modifying & Titrating Regimens: Adjusting dosages, dosage forms, dosage schedules, or routes of administration to attain individualized therapeutic targets (e.g., titrating basal/prandial insulin, uptitrating beta-blockers in heart failure with reduced ejection fraction [HFrEF]).
• Discontinuing & Deprescribing: Stopping medications due to clinical resolution, adverse drug reactions, therapeutic duplications, or lack of efficacy.
• Ordering & Evaluating Laboratory / Diagnostic Tests: Requisitioning blood chemistry panels (serum creatinine, electrolytes), therapeutic drug monitoring levels (vancomycin, digoxin, lithium), glycemic markers (HbA1c), lipid profiles, and urine albumin-to-creatinine ratios (uACR) necessary to guide and monitor drug efficacy and safety.
• Physical Assessment Relevant to Pharmacotherapy: Performing targeted physical examinations (e.g., vital signs, lower extremity edema grading, monofilament foot exams, auscultation of lung sounds) to assess therapeutic response and detect drug-induced toxicities.

                                CDTM SCOPE OF PRACTICE
+-----------------------------------------------------------------------------------------+
|                                 DELEGATED CLINICAL AUTHORITY                            |
+-----------------------+-----------------------+-----------------------+-----------------+
| Initiate Therapy      | Modify / Titrate      | Discontinue / Deprescribe| Order & Evaluate|
| * Add GDMT agents     | * Dose adjustments    | * Adverse event mgmt  | * Serum chemistry|
| * Select dosage forms | * Interval changes    | * Therapeutic duplicate| * Biomarkers/A1c|
| * Vaccine schedules   | * Class substitutions | * Ineffective agents  | * TDM drug levels|
+-----------------------+-----------------------+-----------------------+-----------------+
|                       Targeted Physical Assessment (Vitals, Edema, Foot Exams)          |
+-----------------------------------------------------------------------------------------+

2. Essential Structural Elements of a Valid CPA

State pharmacy practice acts vary in specific statutory language, but national professional consensus standards (e.g., CDC, ACCP, ASHP, APhA) define mandatory structural elements required for a legally enforceable and operationally sound Collaborative Practice Agreement.

3. Statewide Protocols & Pharmacist Prescriptive Authority

In addition to individualized CPAs, state legislatures and boards of pharmacy have established statewide protocols, standing orders, and independent prescriptive authority models. These frameworks empower pharmacists to furnish specific preventative and public health medications directly to the public without requiring a patient-specific collaborative agreement with a local physician.

Core Public Health Prescriptive Authority Categories

1. Opioid Overdose Reversal (Naloxone)

• Authority Model: Standing order, statewide protocol, or direct statutory prescriptive authority across all 50 states.
• Clinical Indications: Furnished to individuals at risk of opioid overdose (high daily MME [≥50 MME/day], concurrent benzodiazepine use, history of overdose, substance use disorder) or concerned third-party family members/bystanders.
• Formulations: Intranasal naloxone spray (4 mg or 8 mg), auto-injectors, intramuscular injectable formulations.
• Counseling Mandate: Recognition of overdose signs (respiratory depression, pinpoint pupils, unresponsiveness), 911 activation, administration technique, and rescue breathing.

2. Hormonal Contraception

• Authority Model: Statewide protocol or independent pharmacist prescribing (enacted in over 30 states).
• Formulations Covered: Oral contraceptive pills (combined estrogen-progestin and progestin-only pills), transdermal patches, vaginal rings, and subcutaneous depot medroxyprogesterone acetate (DMPA).
• Mandatory Clinical Screening: Self-administered medical history questionnaire based on the CDC Medical Eligibility Criteria for Contraceptive Use (CDC MEC), seated blood pressure measurement (combined hormonal contraceptives contraindicated if BP ≥140/90 mmHg or history of thromboembolism/migraine with aura), and routine referral for cervical and breast cancer screening.

3. Tobacco Cessation Therapy

• Authority Model: Statewide protocol allowing pharmacists to initiate FDA-approved cessation pharmacotherapy.
• Agents Authorized: Nicotine Replacement Therapy (NRT: transdermal patch, gum, lozenge, nasal spray, inhaler), Varenicline (Chantix), and Bupropion SR (Zyban).
• Protocol Requirements: Tobacco use history assessment, readiness-to-quit evaluation (5 A's framework: Ask, Advise, Assess, Assist, Arrange), screening for contraindications (e.g., seizure history or eating disorders for bupropion; severe neuropsychiatric symptoms for varenicline), and integration with structured behavioral support programs.

4. Adult & Pediatric Immunizations

• Authority Model: Protocol-based or independent prescribing authority across all states for Advisory Committee on Immunization Practices (ACIP)-recommended vaccines.
• Key Clinical Requirements: Vaccine Information Statement (VIS) provision, administration documentation in state Immunization Information Systems (IIS / registries), anaphylaxis emergency management protocol (epinephrine auto-injector availability), and notification of the patient's primary care provider.

5. HIV Pre-Exposure (PrEP) & Post-Exposure Prophylaxis (PEP)

• Authority Model: Statewide protocols (e.g., California SB 159, Colorado, Oregon) authorizing pharmacists to initiate and furnish initial courses of PrEP and complete emergency PEP.
• PrEP Requirements: Confirmed negative HIV Ag/Ab test within 7 days prior to initiation, screening for acute HIV symptoms, baseline renal function assessment (eGFR ≥60 mL/min for tenofovir disoproxil fumarate / emtricitabine [TDF/FTC]; eGFR ≥30 mL/min for tenofovir alafenamide / emtricitabine [TAF/FTC]), Hepatitis B screening, adherence counseling, and maximum 30-to-60-day supply before mandating ongoing primary care linkage.
• PEP Requirements: Emergency initiation within 72 hours of high-risk occupational or non-occupational exposure; full 28-day regimen (e.g., TDF/FTC plus dolutegravir or raltegravir); baseline HIV testing and linkage to post-PEP follow-up testing.

6. CLIA-Waived Point-of-Care Testing (POCT) & "Test-and-Treat"

• Authority Model: Clinical Laboratory Improvement Amendments (CLIA) Certificate of Waiver enabling pharmacies to perform rapid diagnostic testing and initiate targeted antimicrobial or antiviral regimens pursuant to statewide protocols.
• Target Pathogens: Group A Streptococcus (rapid strep test $\rightarrow$ amoxicillin/penicillin or cephalosporin), Influenza A/B (rapid antigen/molecular $\rightarrow$ oseltamivir or baloxavir within 48 hours of symptom onset), SARS-CoV-2 (rapid antigen $\rightarrow$ nirmatrelvir/ritonavir or remdesivir), and Hepatitis C / HIV screening.

4. Telehealth Modalities, Digital Health & Regulatory Compliance

Telehealth has fundamentally transformed ambulatory care pharmacy, enabling clinical pharmacists to deliver Comprehensive Medication Management (CMM), chronic disease monitoring, and transition-of-care follow-up remotely.

Telehealth Modalities in Ambulatory Practice

1. Synchronous Telehealth (Real-Time Interactive):

   • Involves two-way, live interactive audiovisual communication (or audio-only telephonic encounters when video is inaccessible) between the pharmacist and patient.
   • Ambulatory Applications: Video-based CMM visits, insulin titration consults, inhaler technique demonstration, medication reconciliation, and motivational interviewing.
   • Key Workflow Step: At the start of every synchronous encounter, the pharmacist must verify the patient's identity, confirm the patient's exact physical location/address (crucial for emergency EMS routing if an acute event occurs), obtain informed consent for telehealth delivery, and ensure the patient is in a private, confidential setting.

2. Asynchronous Telehealth ("Store-and-Forward"):

   • Transmission of medical data, diagnostic images, digital photos, or clinical documentation to the pharmacist for review and subsequent clinical intervention outside of a live encounter.
   • Ambulatory Applications: Reviewing uploaded continuous glucose monitoring (CGM) ambulatory glucose profiles (AGPs), reviewing continuous home blood pressure logs, evaluating photographic skin lesions for drug rashes, or processing patient portal secure messages.

3. Remote Patient Monitoring (RPM) & Remote Therapeutic Monitoring (RTM):

   • Utilization of cellular- or Bluetooth-enabled medical devices (digital BP cuffs, smart weight scales, pulse oximeters, continuous glucometers) that automatically transmit physiological telemetry to the clinic's digital dashboard.
   • Ambulatory Applications: Rapid, weekly antihypertensive titration based on automated 14-day home BP averages; proactive diuretic dose adjustments in heart failure patients based on sudden daily weight fluctuations (e.g., >3 lbs in 24 hours or >5 lbs in 1 week); algorithmic basal insulin titrations.

Licensure & Interstate Practice Regulations

• The Geographic Rule of Licensure: The provision of pharmacy services (including clinical cognitive consultations and CDTM) is legally defined as occurring at the physical location of the patient. Therefore, the practicing pharmacist must hold an active, unrestricted pharmacist license in the state where the patient is physically located at the exact time of the telehealth encounter.
• Interstate Compacts & Reciprocity: Unlike nursing (Nurse Licensure Compact) or medicine (Interstate Medical Licensure Compact), pharmacy has historically lacked an active multi-state licensure compact. While emergency declarations temporarily waived cross-state licensing during public health emergencies, standard practice requires individual state licensure or compliance with state-specific temporary/consultative practice exemptions.
• Federal Practice Exemptions: Pharmacists employed by federal agencies (e.g., Veterans Health Administration [VHA], Department of Defense [DoD], Indian Health Service [IHS]) hold federal practice authority and can practice telehealth across state lines with active licensure in any single U.S. state or territory.

HIPAA Privacy & Security in Digital Encounters

Digital health encounters must comply with Health Insurance Portability and Accountability Act (HIPAA) Privacy and Security Rules:

• Business Associate Agreements (BAAs): Telehealth video platforms (e.g., Zoom for Healthcare, Microsoft Teams for Healthcare, Doxy.me, Epic MyChart Virtual Visits) must execute a formal BAA certifying end-to-end AES 128/256-bit encryption and HIPAA-compliant data storage. Consumer platforms without BAAs (e.g., FaceTime, TikTok, public social media live streams) are strictly prohibited.
• Acoustic & Visual Privacy: Pharmacists delivering remote telehealth services from home or private offices must operate in an enclosed room with closed doors, preventing family members or visitors from viewing protected health information (PHI) or overhearing clinical conversations. Headsets and privacy screen filters are strongly recommended.
• Device Security: All endpoint hardware (laptops, tablets, smartphones) accessing EHRs or telehealth platforms must be enterprise-managed, encrypted at rest, password-protected with multi-factor authentication (MFA), and equipped with automatic timeout lockouts.